Drugs Containing Excipient (Inactive Ingredient) POLYETHYLENE GLYCOLS

« Back to Dashboard

Branded drugs containing POLYETHYLENE GLYCOLS excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Blenheim Pharmacal Inc	ESCITALOPRAM OXALATE	escitalopram	10544-968	POLYETHYLENE GLYCOLS
AR Scientific Inc	COLCRYS	colchicine	13310-119	POLYETHYLENE GLYCOLS
STAT Rx USA LLC	AMBIEN	zolpidem tartrate	16590-009	POLYETHYLENE GLYCOLS

Generic drugs containing POLYETHYLENE GLYCOLS excipient

Company	Ingredient	NDC	Excipient
Roxane Laboratories Inc	zolpidem tartrate	0054-0086	POLYETHYLENE GLYCOLS
West-Ward Pharmaceutical Corp	ergotamine tartrate and caffeine	0143-2120	POLYETHYLENE GLYCOLS
West-ward Pharmaceutical Corp	gemfibrozil	0143-9130	POLYETHYLENE GLYCOLS

Polyethylene Glycol Excipients Market Dynamics and Financial Trajectory

Last updated: October 31, 2026

Polyethylene glycols, also called macrogols, are mature pharmaceutical excipients with stable base demand and faster growth in specialty applications. The market is fragmented across molecular-weight grades, solid and liquid forms, pharmaceutical quality systems, and regional supply chains. Commodity PEG pricing is exposed to ethylene oxide, energy, freight, and plant-utilization costs. Specialty pharmaceutical grades have stronger margins because customers value documentation, low impurities, regulatory history, and supply continuity.

The most durable demand comes from oral dosage forms, laxatives, ointments, creams, liquid formulations, biologic stabilization, and lipid-nanoparticle technologies. PEG 3350 has a large consumer-health market, while higher-purity PEG grades and PEG derivatives support injectable products, biologics, and drug-delivery systems.

What are pharmaceutical polyethylene glycols used for?

Polyethylene glycol is a water-soluble polyether produced by polymerizing ethylene oxide. Pharmaceutical grades are classified principally by average molecular weight and physical state.

PEG grade or range	Typical physical form	Main pharmaceutical use
PEG 200-600	Liquid	Solvent, plasticizer, humectant, liquid formulation vehicle
PEG 1,000-1,500	Semisolid or waxy solid	Ointment bases, suppositories, tablet binders
PEG 3350	Powder or flakes	Osmotic laxative, solid dosage excipient, bowel-preparation products
PEG 4,000-8,000	Solid	Macrogol laxatives, tablet processing, suppositories
High-molecular-weight PEG	Solid or powder	Controlled-release systems, biologic formulation research, polymer modification

PEG 3350 is widely used in over-the-counter laxatives, including products equivalent to MiraLAX. PEG 400 is a common solvent and plasticizer in oral, topical, and ophthalmic products. Macrogol 3350 and macrogol 4000 are used extensively in European laxative products.

PEG is also chemically modified into PEG-lipids, PEG-protein conjugates, and other delivery components. Those products are commercially related to pharmaceutical PEG but are not interchangeable with standard excipient-grade PEG.

How large is the polyethylene glycol excipient market?

No authoritative public source reports a single global market value for pharmaceutical-grade PEG alone. Market-research estimates often combine pharmaceutical PEG with industrial, cosmetic, medical-device, and PEG-derivative sales. Those categories have different pricing and demand drivers.

The commercial market has three economic layers:

1. Commodity and semi-specialty PEG grades used in high-volume oral and topical products.
2. Pharmaceutical-grade grades supported by compendial compliance, validated manufacturing, and regulatory documentation.
3. PEG derivatives and highly controlled materials used in biologics, injectables, nanoparticles, and conjugation chemistry.

The first layer is volume-led and price-sensitive. The second has moderate pricing power. The third has the strongest growth potential and the highest technical barriers, but it is often reported within broader life-science, drug-delivery, or contract-manufacturing revenue.

What is driving PEG excipient demand?

Demand is linked to several pharmaceutical categories:

• Over-the-counter and prescription laxatives.
• Generic tablets, capsules, creams, gels, and suppositories.
• Oral liquids and ophthalmic products.
• Biologic formulation and protein stabilization.
• PEGylated drug substances.
• Lipid nanoparticles for nucleic-acid medicines.
• Preclinical and clinical drug-delivery systems.

Growth in PEG 3350 is tied to constipation treatment, bowel preparation, consumer-health brands, and generic substitution. Growth in high-purity PEG is tied to biologics and advanced delivery systems, where qualification cycles are longer but switching costs are higher.

The strongest long-term demand signal is the expansion of nucleic-acid delivery. PEG-lipids are used in lipid nanoparticles for mRNA and other nucleic-acid products, including COVID-19 vaccines. These materials are specialized PEG derivatives rather than conventional PEG excipients, and their economics depend on proprietary chemistry, manufacturing controls, and customer-specific qualification.

How does the PEG excipient supply chain work?

PEG production depends on ethylene oxide, a hazardous and capital-intensive petrochemical intermediate. The supply chain therefore has exposure to feedstock pricing, plant outages, environmental controls, energy costs, and regional logistics.

Large chemical companies generally manufacture base PEG or related polyether materials at scale. Pharmaceutical-excipient suppliers then provide selected grades, packaging, analytical release, documentation, and regulatory support. Some suppliers are integrated producers; others purchase bulk material and perform purification, milling, blending, or pharmaceutical packaging.

Which companies supply pharmaceutical polyethylene glycol?

The principal supplier group includes major chemical and excipient companies such as BASF, Dow, Croda, Clariant, Merck, NOF Corporation, and regional manufacturers in China and India. Their commercial exposure differs:

Supplier type	Typical position	Margin profile
Integrated chemical producer	Base PEG, broad molecular-weight range, global manufacturing	Lower to moderate
Pharmaceutical excipient specialist	Compendial grades, documentation, packaging, technical support	Moderate to high
PEG-derivative specialist	PEG-lipids, PEGylation reagents, conjugation materials	High, with technical and customer concentration risk
Regional producer	Cost-competitive supply, domestic regulatory support	Variable
Distributor	Local inventory and customer service	Lower, dependent on supplier terms

Public companies generally do not disclose PEG excipient revenue as a separate reporting segment. BASF reports broader Care Chemicals and Nutrition & Care activities. Dow reports larger operating segments that include many nonpharmaceutical products. Croda and Merck report pharmaceutical or life-science categories but do not generally isolate standard PEG excipient revenue. Financial analysis must therefore use product-level pricing, capacity, customer contracts, and broader segment margins rather than reported PEG sales.

What is the financial trajectory for pharmaceutical PEG?

The expected trajectory is stable volume growth with selective margin expansion in specialty grades.

Period	Market condition	Financial implication
2020-2021	COVID-related supply disruption, freight inflation, demand for delivery technologies	Higher logistics and input costs; strong interest in PEG-lipid systems
2022-2023	Energy and raw-material volatility, normalization of pandemic demand	Margin pressure on commodity grades; inventory correction in some channels
2024-2026	More normalized supply, continued biologic and nucleic-acid development	Low-to-moderate base-volume growth; stronger specialty-grade mix
2027 onward	Continued use in generics, consumer health, biologics, and delivery platforms	Stable base business with higher-value growth concentrated in derivatives

Commodity PEG pricing tends to track feedstock and operating costs. Pharmaceutical grades can preserve spreads when suppliers have:

• A qualified manufacturing site.
• Multiple approved molecular-weight grades.
• Low levels of aldehydes, peroxides, ethylene oxide, and 1,4-dioxane.
• Strong extractables and leachables data.
• Reliable change-control procedures.
• Compendial and country-specific documentation.
• Validated packaging and global distribution.

The financial risk is asymmetric. A temporary shortage can raise prices quickly, but excess capacity can compress prices for standard grades. Specialty customers are less price-sensitive because replacing an excipient can require formulation work, stability studies, regulatory filings, and customer approval.

What regulatory standards apply to pharmaceutical PEG?

Pharmaceutical PEG is regulated as an excipient through product-specific drug applications and pharmacopoeial standards rather than through a single universal marketing authorization.

Relevant standards include:

• United States Pharmacopeia-National Formulary, including polyethylene glycol monograph requirements.
• European Pharmacopoeia, where macrogol grades are recognized.
• British Pharmacopoeia and other national pharmacopoeias.
• FDA inactive-ingredient precedent and the Inactive Ingredient Database.
• Good Manufacturing Practice requirements under 21 C.F.R. Parts 210 and 211.
• ICH quality and impurity-control expectations.
• Supplier qualification and change-control requirements imposed by drug manufacturers.

The FDA Inactive Ingredient Database records prior use of excipients by route, dosage form, and maximum potency. It does not function as blanket approval for every PEG grade or every route of administration. Sponsors still need to demonstrate suitability in the finished product.

Quality concerns include residual ethylene oxide, 1,4-dioxane, peroxides, aldehydes, elemental impurities, microbial quality, and lot-to-lot molecular-weight distribution. These controls become more demanding for parenteral, ophthalmic, inhalation, and biologic products.

What patent protection covers polyethylene glycol excipients?

Standard PEG itself is a mature, off-patent material. Basic composition and common excipient uses generally do not provide meaningful exclusivity. Commercial protection instead arises from manufacturing know-how, grade specifications, impurity-control methods, formulations, and customer qualification.

Patent activity is concentrated in:

• PEGylated active pharmaceutical ingredients.
• PEG-protein conjugates.
• PEG-lipid compositions.
• Lipid nanoparticles.
• Long-acting injectable formulations.
• PEG-based controlled-release systems.
• Manufacturing and purification processes.
• Specific PEG molecular-weight distributions or end-group chemistries.

What is the Orange Book status of PEG?

PEG is not a drug product with one central Orange Book listing. The Orange Book lists approved drug products and patents submitted by applicants for those products. A PEG-containing laxative may have product-specific listings, but those listings protect the branded formulation, method, or product configuration, not PEG as a chemical commodity.

For generic PEG 3350 or macrogol products, the principal entry risks usually involve:

• Finished-product formulation differences.
• Inactive-ingredient levels.
• Combination electrolytes.
• Dosing devices and packaging.
• Labeling and method-of-use claims.
• Manufacturing consistency.
• Product-specific patents, where listed.

When does PEG lose exclusivity?

Base PEG has no meaningful remaining compound exclusivity. Standard grades are supplied as mature excipients and can be sourced from multiple manufacturers.

Exclusivity may still exist around a finished drug or derivative:

Asset	Exclusivity question
PEG 3350 excipient	No composition-of-matter exclusivity
PEG-containing branded laxative	Product-specific patents, regulatory exclusivity, or trademark protection may apply
PEGylated drug	Depends on active ingredient, conjugate structure, formulation, and patents
PEG-lipid	Depends on lipid structure, linker, formulation, process, and delivery platform
PEG-based biologic formulation	Depends on the biologic and formulation claims

Paragraph IV challenges are therefore product-specific. A generic sponsor challenging a PEG-containing branded drug may certify against listed patents, but it does not challenge the basic legality of manufacturing PEG. Litigation risk attaches to the finished pharmaceutical product.

What formulation and method-of-use patents protect PEG products?

Formulation patents may cover:

• PEG concentration and molecular-weight range.
• Electrolyte combinations in bowel-preparation products.
• Osmotic laxative compositions.
• PEG-based sustained-release matrices.
• Stabilized biologic formulations.
• PEG-lipid ratios in lipid nanoparticles.
• Buffer systems, pH, cryoprotection, and storage conditions.
• Administration methods and dosing schedules.

Method-of-use patents may cover constipation treatment, bowel cleansing, sustained exposure, immune modulation, or delivery of nucleic acids. Their enforceability depends on claim construction, prosecution history, written-description support, enablement, and jurisdiction.

No single patent family defines the standard PEG excipient market. The main barrier is product and process qualification rather than raw-material patent ownership.

Which companies are challenging PEG-containing products?

Competition is strongest in OTC laxatives and generic prescription products. Generic-drug companies can enter when product-specific patents and regulatory exclusivities expire or are successfully challenged. The competitive field includes large generic manufacturers, regional OTC companies, private-label retailers, and vertically integrated consumer-health businesses.

For PEG-lipid and PEGylated biologic technologies, competition is more concentrated among originator pharmaceutical companies, specialty chemical suppliers, contract manufacturers, and platform-technology licensors. Disputes often concern delivery platforms and active pharmaceutical ingredients rather than standard PEG.

Settlement agreements can delay or structure generic entry through licensed entry dates, supply arrangements, authorized generics, or restrictions on formulation and manufacturing. The existence and terms of such agreements must be assessed at the individual drug-product level because no market-wide PEG settlement controls entry.

What generic launch risks exist for PEG products?

The largest generic-entry risks are regulatory and commercial rather than chemical.

A generic sponsor may face:

• Difficulty matching the reference product's inactive-ingredient profile.
• Product-specific bioequivalence or comparative clinical requirements.
• Patent claims covering combinations or dosing instructions.
• Manufacturing-site qualification delays.
• Limited access to high-purity or specialty PEG grades.
• Shortages during supplier changes.
• Retailer concentration in OTC channels.
• Low price ceilings after multiple entrants.

For PEG 3350 products, large-volume generic competition can reduce prices rapidly. Specialty PEG derivatives have higher switching costs and fewer qualified suppliers, producing better retention and pricing.

How does PEG compare with competing excipients?

PEG competes with glycerin, propylene glycol, polysorbates, poloxamers, povidone, hydroxypropyl cellulose, and other polyethers.

Attribute	PEG	Glycerin	Propylene glycol	Polysorbates	Povidone
Water solubility	High	High	High	High	High
Solid and liquid grades	Broad range	Limited	Mainly liquid	Mainly liquid or semisolid	Broad solid range
Laxative use	Strong	Limited	Limited	No major role	Limited
Oxidation concern	Yes	Yes	Yes	Significant	Yes
Molecular-weight control	Important	Not applicable	Not applicable	Complex	Important
Biologic use	Established, including derivatives	Limited	Limited	Established	Established
Supply-chain maturity	High	High	High	High	High

PEG's advantage is its broad molecular-weight range and established regulatory history. Its weaknesses include oxidation, potential hypersensitivity concerns for PEG-containing drug products, and competition from alternative stabilizers and surfactants in biologics.

What are the main investment and commercial risks?

The base PEG business has limited exposure to patent expiration because it is already mature and largely off-patent. The main risks are:

• Ethylene oxide and energy-price volatility.
• Environmental, health, and safety restrictions.
• Single-site or single-region dependence.
• Supplier consolidation.
• Quality deviations involving trace impurities.
• Customer insourcing or dual sourcing.
• Price erosion in laxatives and generic products.
• Substitution by alternative excipients.
• Reduced demand for specific PEG-lipid platforms.
• Regulatory scrutiny of PEG-related hypersensitivity and anti-PEG antibodies.

The main upside is mix improvement. Suppliers that move from standard PEG 400 or PEG 3350 into validated injectable grades, PEG-lipids, conjugation reagents, and high-purity biologic materials can expand margins without requiring equivalent volume growth.

Key Takeaways

• Pharmaceutical PEG is a mature, diversified excipient market with stable base demand.
• PEG 3350 and macrogol products provide high-volume revenue but face generic and OTC price pressure.
• Specialty PEG grades and PEG derivatives have stronger growth and margin potential.
• Standard PEG is generally off-patent; meaningful exclusivity lies in formulations, PEGylated drugs, PEG-lipids, delivery systems, and manufacturing processes.
• PEG has no single Orange Book status. Patent and Paragraph IV analysis must be performed for each finished drug product.
• Public companies rarely disclose PEG revenue separately, making product-level and segment-level analysis necessary.
• Supply security, impurity control, regulatory documentation, and qualified manufacturing capacity are the main commercial barriers.
• Financial performance should improve with specialty-grade mix, but commodity grades remain exposed to feedstock costs and price competition.

FAQs

Is polyethylene glycol an active pharmaceutical ingredient or an excipient?

PEG is generally an excipient, but PEG 3350 has pharmacological activity as an osmotic laxative. PEG derivatives can also be part of active drug substances, including PEGylated proteins and other conjugates.

Is PEG 3350 patented?

The basic PEG 3350 material is not protected by active composition-of-matter exclusivity. Individual PEG 3350 products may have product, formulation, method-of-use, trademark, or regulatory protections.

Are PEG-lipids the same as PEG excipients?

No. PEG-lipids are chemically modified PEG derivatives used in delivery systems such as lipid nanoparticles. They require separate technical, regulatory, and intellectual-property analysis.

Does the FDA approve PEG suppliers?

The FDA does not provide a single universal approval for every PEG supplier. Drug manufacturers qualify excipient suppliers through audits, specifications, testing, GMP controls, and regulatory documentation.

What is the biggest financial opportunity in the PEG market?

The strongest opportunity is in high-purity PEG derivatives and specialty materials for biologics, nucleic-acid delivery, PEGylation, and injectable formulations. Standard PEG grades remain dependable but offer less pricing power.

References

1. European Directorate for the Quality of Medicines & HealthCare. (2023). European Pharmacopoeia (11th ed.). Council of Europe.

2. International Council for Harmonisation. (2023). ICH Q3C(R8): Impurities: Guideline for residual solvents. ICH.

3. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. U.S. Food and Drug Administration. (2024). Electronic Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

5. U.S. Food and Drug Administration. (2024). Current good manufacturing practice for finished pharmaceuticals, 21 C.F.R. Parts 210-211. https://www.ecfr.gov/

6. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP-NF.